Ocugen(US:OCGN)2025-11-05 12:30Financial Performance - Total revenue for Q3 2025 was $1.752 million, compared to $1.136 million in Q3 2024, representing a 54.3% increase year-over-year[19] - Total operating expenses for Q3 2025 were $19.377 million, up from $14.388 million in Q3 2024, reflecting a 34.7% increase[19] - The net loss for Q3 2025 was $20.051 million, compared to a net loss of $12.970 million in Q3 2024, indicating a 55.2% increase in losses year-over-year[19] - Research and development expenses for Q3 2025 were $11.149 million, compared to $8.108 million in Q3 2024, marking a 37.5% increase[19] Cash Position - Cash, cash equivalents, and restricted cash totaled $32.9 million as of September 30, 2025, down from $58.8 million as of December 31, 2024[11] - The company closed a $20 million registered direct offering in Q3 2025, which is expected to extend the cash runway into Q2 2026[6] Clinical Trials and Development - Enrollment in the OCU400 Phase 3 liMeLiGhT clinical trial is nearing completion, with 50% enrollment achieved to date[5] - The OCU410ST Phase 2/3 GARDian3 trial is ahead of schedule, with interim data expected mid-year 2026[5] - The company intends to file three Biologics License Applications (BLAs) in the next three years, with the first expected in 1H 2026[2] Partnerships and Sales Projections - The company has an exclusive licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea, projected to generate $180 million in sales over the first 10 years[2]